HUE034251T2 - Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása - Google Patents

Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása Download PDF

Info

Publication number
HUE034251T2
HUE034251T2 HUE10782040A HUE10782040A HUE034251T2 HU E034251 T2 HUE034251 T2 HU E034251T2 HU E10782040 A HUE10782040 A HU E10782040A HU E10782040 A HUE10782040 A HU E10782040A HU E034251 T2 HUE034251 T2 HU E034251T2
Authority
HU
Hungary
Prior art keywords
lys
ser
asn
thr
asp
Prior art date
Application number
HUE10782040A
Other languages
English (en)
Inventor
Paolo Costantino
Maria Rosaria Romano
Francesco Berti
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE034251(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE034251T2 publication Critical patent/HUE034251T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • C07H1/08Separation; Purification from natural products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (2)

  1. SZABADALMI KifeNVPONTOK; 1, bptdozémotekuíához ka$agá%. 3L mummbM·. szárniáéo & dpbié kapszuláé pöIísxMPIrie él ép löido^6«K?tóka|álsoz |is|«p?k if: «I® Is llpösö :b|ïs®ilfe :p!toctefc wmttmé llpp^^tÉk^Â^ eíolíIMsám, mely efárás iÄlOilkll I köfÄ~ zdfcsk (à) eb ázás k&p&uiâris po!e?ach»rid tisztításét» 5. típusé S «««vwv leitekből, mely 'ttâslmax «gy^ •pest, oie b-beu s kapszuiarb pobszachoriäoi feKzabadOjek u sejtekbe· e xejiek savas kc?.e!êse biudk îîJïoI a sejrek nedves scjtmasäM ibrmâjâbsn vsooak vagy vtzee közegben s/us?.peodálv»:ve»n»kf:is & ffegi|öi p;>! issaebád d moíek idaíömege 2-ls §00 kDa; dd a k*p»;ttVtiiN pofeuouiOuU konjugálásé agy inu Johnok ki kdhu' krigugiíum rí xdiUu,Jt veíwho: # IC) a konjugátum eîkeverése egy hordozámoiekníáboz koojag&H, 5. ííureaxból sxánnazó $ típusú
  2. 2. Fi járna egy kerdözimátóísMhö^: koeiygétt f. öí^msMÍ származó 8, IfpMu kípzidáfi poliszach&amp;ridot és egy borduzémoíekuláho?. konjugált -S. itt/mtíből százMké I. típusé kapizidáiys pokvacn esdoí toltam izo sor ujpogtm ke-, urnem de · hk 'siivu u\ >x auide k'tohna^i a kőtelke- zôkub ,as y P' k^p«.?rk^i' PO \ubottd tt*> h,-us 8 4 p ^ < < ' vfkV >1 hk x su Oint eg> Se pfsk melyben a fefpszuSéris poifazocharâN fe Fra bad rusk s sojíekbbl a sejtek savas keltése öpatk ahol a fejtek nedves zejinuss.í&amp; íbrutéjábsa vannak vagy vises fcöldgbeg gägtgypeudltvk vaunglg el a tisztítóit poliszsdi&amp;sid mulekukiíínnege 2-0500 kid; (b> a kapszulám prdSszach&amp;nd koujugáte egv b#Âià:idÉb|^Âé^sÂj^#Âtu eis*àihtô*>a gépből; èS lel a kemjugámm elkevetéss egy hordozómtde-kuláboz koniugáit. S .m««sMÍ szúmmxé S. típusú kapszulám polisz&amp;chariddai. J, Az í. vagy 2.. íglttypgs szerinti eijátá\.s gbol p| a savas kezelést eoetsav dkdmadísávd végezzék és/vagy (ü) az eljárás tartalmaz továbbá egy semlegesítési lépést. 4, s V 0 o {get νρ idő* be vt w ^ u vH i.s x s íz > b V'V î» f»' 'Uí U'vitbbo \y k;\'^ ' ttík cemritbgáiásáírn és a poltoebarid^artaimtVteluIteé be gyíy lésére. iS. Äz 1-4. igénypontok bármely *ko szerinti eljárás, ahol a* eljárás a* <a) lépésben tartalmaz továbbá >-«gy lépást a kapszulám poliszáéba* hl DNte&amp;i évvagy ílf Imi IfriésA kszálékérfe, P. -w } -S igenypmuok bm melyike w.ermn elírnák aboi az esjárá\ tsz. tat lépésKa tarmlosa? továbbá Sí- xs kost!? \ t ÜV<K' » 0 '<»*«» ï Î. ! > N K' ' \í >s \ \? ^ 'y ,V> p.-VRi .k Ι',ίΓΗΚ k Ike v V. írt .'SUT ίϊ-, Λ'Ι.ίί dj.rtá·. ! ' M k\X 'Km kk VíXAí \, KV, mK a k4vetkezÁ>ket: |a) egy rimezümsi lépés; I b) egy anhnppré'IS .kromatográfiás lépés; <£> egy géhzürési KxK émYam (d'> egy lépés a polisz-ieharid mméityitésére,. \M ”* t$*H\p""k>k KinnJvíU vMud ehatu-N ahol az φιτΛ u/ v4' lépesbe» t K>dm.\>z»;:.tovabba a következőkéi? > ,¾ I.A·, i <n|ols ie » s>f, o sem· hk, V tiv! (d) úgy xterilMbém lépés. |4, Igénypontok |«gí||p«?|f|8tl eljárás, ahol az epÄ m- (áj MgÄal op kivkt|ezik«t: brialmazié tósmtményi mrdménymo «a> a polis >aeh*mdol es, peptkVghkaa szemnezovkst, ouknek tsissflslps f oBszaobat» eHü* gère vonatkoztatva kevesebb., mini 5 töinegvk pepüéoglikán; és? vagy B|j s pplisMelÄbi és fehérje szenny e/Klést rneiyá|krirsmtnyisége a pnhszaehnrnl össztömeprp: ':-ν0?ί®|^ϋΙΐ^'kw^bh, mmt 5 tömegé fehérje. Uh Az !«>. igénypontok bármelyike szerinti éljÄ.síít: eredményez. amely a pölíszaeiiarkkst és nukteinsav szennyeződést tartalmaz, a^lyatak matmyaságe a puiiszsckarlá Isazbtaagéraasmatedatva kevesebb, trnm '> sümagU «nkfcún«sav Π. Az Mö. igénypontok bármelyike szerinti eljárás, amely tartalmazza továbbá a következe eső-portból vuMemn egy \ axy ;Mls s zna leik' e ,x'myx ivLri'MS.ri wm a ke\znme,-u\ <<gv eb \ a' tigéa; egy «IfB auligéo; egy sdri-2 antigén; egy sdrC antigén; egy sasF antigén; egy·' emp anfigéa; egy sátD antigén; egy spa antigén; egy esaC amidén: egy ttóittl utítíféa; aiy staOOi m*. rigón; egy ísdC antigén; egy HI&amp; antigén; egy staOl ) amigén; egy ísáA antigén; egy isdB antigén- e.> egy sts073 antigén.
HUE10782040A 2009-10-30 2010-11-01 Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása HUE034251T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25690509P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
HUE034251T2 true HUE034251T2 (hu) 2018-02-28

Family

ID=43513776

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10782040A HUE034251T2 (hu) 2009-10-30 2010-11-01 Staphylococcus aureusból származó 5. típusú és 8. típusú kapszuláris szacharidok tisztítása

Country Status (22)

Country Link
US (5) US9060965B2 (hu)
EP (2) EP3199177A1 (hu)
JP (4) JP5914344B2 (hu)
CN (2) CN109134677A (hu)
AU (1) AU2010310919B2 (hu)
BR (2) BR112012010223A2 (hu)
CA (1) CA2779578A1 (hu)
CL (1) CL2012001145A1 (hu)
CY (1) CY1118905T1 (hu)
DK (1) DK2493498T3 (hu)
ES (1) ES2626416T3 (hu)
HR (1) HRP20170674T1 (hu)
HU (1) HUE034251T2 (hu)
LT (1) LT2493498T (hu)
MX (2) MX345967B (hu)
PL (1) PL2493498T3 (hu)
PT (1) PT2493498T (hu)
RS (1) RS56000B1 (hu)
RU (1) RU2579900C2 (hu)
SG (1) SG10201407096RA (hu)
SI (1) SI2493498T1 (hu)
WO (1) WO2011051917A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
RU2531234C2 (ru) 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
JP2013506651A (ja) * 2009-09-30 2013-02-28 ノバルティス アーゲー Staphylococcus.aureus5型および8型莢膜多糖の結合体
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
JP2014507142A (ja) * 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス,インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN110563818A (zh) 2012-08-31 2019-12-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2015010185A1 (en) * 2013-07-26 2015-01-29 University Of Saskatchewan Methods for producing salmonella o- antigen capsules, compositions and uses thereof
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
CN112986457B (zh) * 2021-02-25 2022-07-12 中国食品药品检定研究院 HPSEC-MALS法检测多糖并与Sepharose CL-4B法关联的方法
CN113234770B (zh) * 2021-06-15 2024-06-14 广州知易生物科技有限公司 脆弱拟杆菌荚膜多糖a的制备方法
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN114957509B (zh) * 2022-08-01 2022-10-21 深圳柏垠生物科技有限公司 一种可放大的可拉酸纯化方法

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2166963A (en) * 1936-11-19 1939-07-25 Sharp & Dohme Inc Antigenic polysaccharide complex
FI40107C (fi) * 1961-05-15 1968-10-10 Parke Davis & Co Menetelmä uuden stafylokokkiantigeenin valmistamiseksi
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
GB995338A (en) * 1963-09-20 1965-06-16 Parke Davis & Co Polysaccharides and methods for their production
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JP4087896B2 (ja) * 1991-11-22 2008-05-21 ナビ・バイオフアーマシユテイカルズ スタフィロコッカス・エピダーミジス関連i及びii型表面抗原
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
CZ390297A3 (cs) 1995-06-07 1998-05-13 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
CA2284606A1 (en) 1997-03-26 1998-10-01 Brigham And Women's Hospital, Inc. Method for generating saccharide fragments
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
KR100769103B1 (ko) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP5102414B2 (ja) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 髄膜炎菌抗原および組成物
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1144998A3 (en) 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6689567B1 (en) * 1999-05-28 2004-02-10 University Of Guelph Method for assaying the function of FlaA1 and WbpM
CN1416352B (zh) 2000-01-17 2011-05-25 启龙股份公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6537577B1 (en) * 2001-06-04 2003-03-25 Bio Medical Development Corporation Method of prophylaxis for bovine mastitis
GB2379996B (en) * 2001-06-05 2004-05-19 Tayside Flow Technologies Ltd Flow means
WO2002101026A2 (en) * 2001-06-11 2002-12-19 Applied Nanosystems B.V. Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
EP1597348A4 (en) 2002-08-26 2010-03-31 Novartis Vaccines & Diagnostic GENES OF STREPTOCOCCUS PRESERVED OR SPECIFIC
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP1551357B1 (en) 2002-09-13 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus vaccine
ES2648046T3 (es) * 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacárido para infecciones estafilocócicas
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1787839B (zh) * 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
DE602004010376T2 (de) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
JP4764820B2 (ja) * 2003-06-23 2011-09-07 バクスター・インターナショナル・インコーポレイテッド ワクチン用担体タンパク質
WO2005009378A2 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2532370A1 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
ATE460498T1 (de) * 2003-09-11 2010-03-15 Staat Der Nederlanden Vert Doo Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1725575B1 (en) 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1725255A4 (en) 2004-02-27 2007-07-11 Merck & Co Inc POLYPEPTIDES FOR INDUCING AN IMMUNE RESPONSE PROTECTING AGAINST STAPHYLOCOCCUS AUREUS
US20050250821A1 (en) * 2004-04-16 2005-11-10 Vincent Sewalt Quaternary ammonium compounds in the treatment of water and as antimicrobial wash
US7842479B2 (en) * 2004-05-21 2010-11-30 The Board Of Regents Of The University Of Nebraska Methods for altering acetic acid production and enhancing cell death in bacteria
JP2008500043A (ja) 2004-05-25 2008-01-10 メルク エンド カムパニー インコーポレーテッド 黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2579225A1 (en) 2004-09-17 2006-03-30 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US7718182B2 (en) 2005-01-21 2010-05-18 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
PT2351578T (pt) * 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
EP1937304A2 (en) * 2005-08-24 2008-07-02 Novartis Vaccines and Diagnostics S.r.l. Zwitterionization of capsular saccharides
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007084856A2 (en) * 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
CN101466406B (zh) 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
GB0612854D0 (en) * 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
WO2008055501A1 (en) * 2006-11-08 2008-05-15 B-K Medical Aps Method and apparatus for two-step sterilization
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CN101679516B (zh) 2007-05-31 2013-11-13 默沙东公司 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
JP5680536B2 (ja) * 2008-09-17 2015-03-04 ノバルティス アーゲー 組み合わせgasワクチンおよび治療法
AU2009302582A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
RU2531234C2 (ru) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013506651A (ja) * 2009-09-30 2013-02-28 ノバルティス アーゲー Staphylococcus.aureus5型および8型莢膜多糖の結合体
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
JPWO2011081075A1 (ja) * 2009-12-28 2013-05-09 キッコーマン株式会社 黄色ブドウ球菌抗原の抽出方法、黄色ブドウ球菌抗原の抽出用試薬および黄色ブドウ球菌の判定方法
EP2519265B1 (en) * 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
CN103037885B (zh) * 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CA2932225C (en) 2013-12-04 2023-01-17 Glycovaxyn Ag Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
US9775872B2 (en) 2014-08-20 2017-10-03 Professional Compounding Centers Of America Topical pharmaceutical bases for preventing viral diseases
WO2018217564A1 (en) * 2017-05-22 2018-11-29 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis

Also Published As

Publication number Publication date
US20120282295A1 (en) 2012-11-08
US9060965B2 (en) 2015-06-23
US20190169216A1 (en) 2019-06-06
US20220089627A1 (en) 2022-03-24
PT2493498T (pt) 2017-05-24
EP3199177A1 (en) 2017-08-02
JP2019104940A (ja) 2019-06-27
CY1118905T1 (el) 2018-01-10
RS56000B1 (sr) 2017-09-29
EP2493498A1 (en) 2012-09-05
US11208424B2 (en) 2021-12-28
CA2779578A1 (en) 2011-05-05
SG10201407096RA (en) 2014-12-30
US20150315225A1 (en) 2015-11-05
WO2011051917A1 (en) 2011-05-05
LT2493498T (lt) 2017-05-25
CN102971009A (zh) 2013-03-13
EP2493498B1 (en) 2017-03-22
ES2626416T3 (es) 2017-07-25
BR112012010223A2 (pt) 2016-12-06
JP2013509397A (ja) 2013-03-14
AU2010310919B2 (en) 2015-05-07
BR122019005883A8 (pt) 2022-10-04
CL2012001145A1 (es) 2012-09-14
JP2017206564A (ja) 2017-11-24
DK2493498T3 (en) 2017-05-08
US20160376301A1 (en) 2016-12-29
RU2579900C2 (ru) 2016-04-10
JP5914344B2 (ja) 2016-05-11
PL2493498T3 (pl) 2017-08-31
HRP20170674T1 (hr) 2017-07-14
CN109134677A (zh) 2019-01-04
US9441004B2 (en) 2016-09-13
SI2493498T1 (sl) 2017-07-31
MX345967B (es) 2017-02-28
MX2012004851A (es) 2012-05-22
JP2016047852A (ja) 2016-04-07
AU2010310919A1 (en) 2012-05-24
BR122019005883A2 (hu) 2019-09-03
RU2012122237A (ru) 2013-12-10

Similar Documents

Publication Publication Date Title
US11208424B2 (en) Staphylococcus aureus type 5 capsular saccharides
AU2006211049B2 (en) Purification of streptococcal capsular polysaccharide
US10736959B2 (en) Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BE1024282B1 (fr) Compositions immunogènes